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There are two important gaps of knowledge in depression treatment, namely the
lack of biomarkers predicting response to antidepressants and the limited knowledge
of the molecular mechanisms underlying clinical improvement. However, individually
tailored treatment strategies and individualized prescription are greatly needed given
the huge socio-economic burden of depression, the latency until clinical improvement
can be observed and the response variability to a particular compound. Still, individual
patient-level antidepressant treatment outcomes are highly unpredictable. In contrast
to other therapeutic areas and despite tremendous efforts during the past years, the
genomics era so far has failed to provide biological or genetic predictors of clinical utility
for routine use in depression treatment. Specifically, we suggest to (1) shift the focus
from the group patterns to individual outcomes, (2) use dimensional classifications such
as Research Domain Criteria, and (3) envision better planning and improved connections
between pre-clinical and clinical studies within translational research units. In contrast
to studies in patients, animal models enable both searches for peripheral biosignatures
predicting treatment response and in depth-analyses of the neurobiological pathways
shaping individual antidepressant response in the brain. While there is a considerable
number of animal models available aiming at mimicking disease-like conditions such
as those seen in depressive disorder, only a limited number of preclinical or truly
translational investigations is dedicated to the issue of heterogeneity seen in response
to antidepressant treatment. In this mini-review, we provide an overview on the current
state of knowledge and propose a framework for successful translational studies into
antidepressant treatment response.
Keywords: animal model, antidepressant, depression, non-response, response, response prediction, translational
medicine
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INTRODUCTION
Major depressive disorder (MDD) is the second leading
cause of disease burden worldwide, thus constituting
serious socio-economic threat for modern societies (1, 2).
Combined epidemiological and economic data on depression
in Europe revealed that it is the most costly brain disorder
in Europe with the cost of depression corresponding to
1% of the total economy of Europe (2). There are different
approaches and strategies to treat MDD in adults, ranging
from pharmacological and psychotherapeutic interventions
to transcranial magnetic stimulation, electroconvulsive
therapy to deep brain stimulation (3). The “National
Institute for Health and Care Excellence (NICE)” guideline
recommends antidepressant pharmacotherapy as a crucial
pillar in the treatment for all patients with moderate to severe
depression (3).
The choice of a particular antidepressant agent for an
individual patient currently is based on treatment guidelines,
experience, individual medical comorbidities, but unfortunately
largely based on “trial and error” (4). Despite decades of research
and international efforts to collect cohorts for genetic studies, we
still lack a fundamental understanding of the pathophysiology
for any of the classical psychiatric disorders, including MDD.
In other therapeutic areas such as diabetes or heart diseases
(5) a considerable proportion of hits for disease-associated
genes in genome-wide association studies (GWAS) match with
the targets of already marketed drugs. Precision medicine
and individualized therapy has dramatically and successfully
improved both our understanding and the treatment of certain
somatic diseases. For example, 5-year-survival in children with
acute lymphatic leukemia increased from 10% in 1990 to
90% in 2005 (6). Unfortunately, the situation is completely
different in neuroscience research, where one conspicuous
observation from the genetics of depressive disorders is that
none of the scores of candidates from GWAS involves the usual
psychopharmacologic suspects, i.e., monoamine transporters
or their receptors (4). Importantly, the genetic risk variants
identified thus far cover a broad spectrum of biological processes
but are enriched in neurodevelopmental or synaptic genes.
Taken together, these results point to new pathways involved in
pathophysiology, suggesting an entirely new biology for mental
disorders and the urgent need to reconsider mental illnesses
as “syndromes of disrupted neural, cognitive, and behavioral
systems” (7).
But how do we move from genomic variants to better
treatments? Before conceptually novel and improved treatment
strategies can be envisioned, we urgently need to focus
on a more precise understanding of the neurobiological
mechanisms underlying mental disorders and individual patient
response to pharmacotherapy by appropriate translational
approaches. Currently only a limited number of preclinical
or truly translational investigations is dedicated to the
issue of heterogeneity seen in response to antidepressant
treatment.
CURRENT CHALLENGES IN
ANTIDEPRESSANT DRUG TREATMENT:
TO RESPOND OR NOT TO RESPOND,
THAT IS THE QUESTION
The large heterogeneity in response to antidepressant treatment
(8) is a major problem in depression treatment. Although
the available treatments are safe, both psychiatrists and
patients have to cope with a considerable variability in
antidepressant treatment outcome: 20–30% of the patients
treated with antidepressant drugs fail to respond to two or more
pharmacological interventions (9). There are no biomarkers
available monitoring treatment response, disease state, or
predicting individual response to a particular compound (10).
Thus, the most effective antidepressant medication for each
patient can presently only be identified through trial and error
and needs several weeks to test for each given compound. If
early on we could predict that a chosen medication will likely
be ineffective for an individual patient, we could dramatically
reduce costs and patient suffering and increase treatment efficacy.
Therefore, the identification of individual factors predicting
treatment response is one of the most pressing needs in
depression treatment. Predictive biomarkers or biosignatures
would not only allow to predict or monitor treatment response in
clinical practice with marketed drugs but could—if compound-
independent—also assist in the evaluation of drug actions of
novel compounds at an early stage in clinical trials which are
frequently marred by late attrition. This is even more important
as over the last decades, encouraging preclinical evidence using
animal models pointed to innovative pharmacological targets to
treat MDD, such as antagonists of the corticotropin releasing
hormone receptor type 1 (11) or substance P receptor antagonists
(12). These compounds have entered clinical trials with high
hopes for a breakthrough in depression treatment, but they have
failed to show convincing results. These failures have called into
question as to how well traditional animal models for depression
can translate to clinical efficacy (13).
Altogether, this illustrates the urgent need to develop
improved translational models to better understand the
neurobiological mechanisms that underlie MDD and to more
specifically assess response to antidepressant treatment. We
here review recent progress and highlight some of the best leads
to diversify and improve discovery end points for preclinical
depression research and treatment response in nonhuman
organisms.
ANIMAL EXPERIMENTAL APPROACHES
TO MODEL DEPRESSION AND
ANTIDEPRESSANT TREATMENT
EFFICACY: INDIVIDUALITY MATTERS
Why should we use animals to model complex diseases like
MDD?What could be the strengths of an animal model, and what
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are its limitations? From a psychiatrist’s point of view, it is difficult
to agree that rodent or even species such as zebrafish could be of
value to investigate a complex mental disorder characterized by
a set of diverse symptoms such as MDD. The same holds true
for the issue of response to psychopharmacological treatment.
A large heterogeneity in the symptomatology of MDD and a
close association with other comorbid psychiatric disorders in
a substantial proportion of MDD patients are major drawbacks
and confounding factors for clinical studies (14). The exclusive
use of peripheral tissue like blood can only be of limited value
in deciphering the neurobiology of depression, as the brain can
only be accessed indirectly, e.g., by neuroimaging approaches
(14). In addition, human post-mortem brain samples suffer
from many confounding variables like variation in pH, molecule
degradation, age bias, and a bias toward suicide victims (14).
In contrast, animal models offer unique advantages such as
high level of standardization. Working with standardized animal
cohorts can help to minimize biases, to deal with larger sample
sizes, e.g., when dealing with small, cost-efficient species such as
zebrafish and finally, they allow unrestricted access to the organ
of interest, i.e., the central nervous system (14–16).
The potency of an animal model can be described based
on three key elements: construct, face, and predictive validity
(17, 18). Construct validity is present in MDD animal models,
if depressive-like behavior and associated features can be clearly
and unambiguously seen and interpreted in the model (17). The
criterion of face validity is met if the model possesses similar
or comparable elements in terms of “anatomical, biochemical,
neuropathological or behavioral features” between animal and
human (18). Predictive validity focuses on the ability of an
animal model to serve as a tool for pharmacological research:
Antidepressant agents, which induce antidepressant-like effects
in animals, should also show similar or comparable effects in
humans (17, 18). Based on these criteria, the strength of an
animal model system can be estimated. Behavioral aspects of
MDD-related phenotypes as well as behavioral tests to address the
effects of antidepressant agents have been characterized within
various animal experimental approaches: to model depression-
like phenotypes, a number of different strategies has been
used, e.g., selective breeding or applying stress during distinct
windows of vulnerability of the animal’s life to induce long-
lasting behavioral and neurobiological changes. For excellent
and recent in-depth reviews on animal models of depression-
like conditions and more recent attempts to model circuit-based
symptomatic dimensions in MDD see (14, 19). Considering the
plethora of different attempts to model MDD-like phenotypes
in the last decades, concluding that we need to fundamentally
re-think animal models for depressive disorders might sound
pretentious. However, how else can we overcome the current
limitations and advance the field to finally translate basic progress
into better care for our patients?
In the context of antidepressant research, the majority of
animal models and related publications traditionally analyze
and discuss an average effect of treatment or manipulation
versus the respective control condition. There is only very
limited insight into the question of why so many patients
do not show a response, despite the fact that antidepressants
have been proven to be effective in general. Unfortunately, the
enigma of heterogeneity in antidepressant response has not
been systematically addressed to date although it has long being
recognized as one of the critical factors hampering antidepressant
drug discovery, clinical evaluation, and approval of potentially
novel compounds. Therefore to pave the way for so-called
precision psychiatry, we would like to propose a framework for
translational studies into individualized medicine in psychiatry.
Individuality—commonly defined as the collection
of divergent behavioral and physiological traits among
individuals—develops when unique environmental influences
act on the genome, following complex routes, to produce
phenotypic diversity. Individuality is considered central to the
development of several neuropsychiatric disorders. Focusing on
individuality rather than average outcomes has gained more and
more attention both in rodents (20) and in zebrafish (21).
Approaches to focus on heterogeneity and individuality
within a cohort of mice have been quite successfully used in
the context of stress research to identify putative neurobiological
pathways modulating individual susceptibility and resilience: In
2007, the Nestler group published the results of a groundbreaking
study, where they did not analyze the mere effect of a
certain manipulation (in this case a chronic social defeat stress
paradigm), but stratified each individual mouse based on its
performance in a defined behavioral test of social interaction
as outcome (22). Stratification of the animals based on their
performance in the social interaction test allowed to focus on
the differences within the experimental group, accompanied by
the advantage that the two new “extreme” subgroups (above
or below a certain threshold) become more homogeneous
(22), which might facilitate the discovery of true candidates.
In resilience research, this stratification approach has proven
successful in a number of excellent publications during the last
years (23–25). Aiming at the identification of the neurobiological
mechanisms underlying response to antidepressant treatment,
we recently established an animal experimental approach using
stratification into extreme subpopulations out of a considerably
large number of inbred, genetically homogeneous mice in
response to antidepressant treatment [Figure 1, (26)]. In addition
to the significant average group effect between antidepressant
and vehicle-treated groups, we continued to select, out of the
cohort of paroxetine-treated animals, subpopulations of good,
and poor responders based on their outcome in one of the
major behavioral tests assessing antidepressant-like efficacy in
rodents. Indeed, we were able to identify specific transcriptome
signatures associated with response status in murine blood and
to successfully translate and validate the findings from our
animal model in a cohort of depressed patients (26). Finally,
we could reveal a particular role of the glucocorticoid receptor
(GR) in shaping response to antidepressants, which is even more
interesting considering that those data have been generated by
an animal model using a hypothesis-free approach. The putative
role of the GR in modulating antidepressant-like effects had been
suggested already earlier by means of hypothesis-driven basic
and clinical depression research [for review: (27)], supporting
the validity of our model. We believe that this was the first step
toward amore in-depth and dimensional analysis of different and
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FIGURE 1 | Schematic overview illustrating an example of successful translational research focusing on antidepressant treatment response. (A) Treated with
antidepressant agents (A left), human patients suffering from depression show a reduction of depressive symptomatology, assessed with several depression scores,
like Hamilton Depression Rating Scale with 17 questions (HAMD17) and the Inventory of Depressive Symptoms, rated by clinicians (IDS-C30) and patients
(IDS-SR30). Although overall benefit from antidepressant agents takes place, individual patients clearly differ from each other. Stratified in good (blue) and poor (purple)
responders, this reveals the large heterogeneity of antidepressant treatment response as an important clinical problem. A recently published animal model (26)
translates this problem into mice (A right), where stratification into good and poor responders of antidepressant treatment is similarly possible. Mice are stratified into
responder groups based on the Forced Swim Test, a commonly used test for depressive-like behavior. (B) Such animal models offer the key advantages of both
biomarker research and analysis of the associated, neurobiological pathways. Blood samples collected from mice and human patients can be aligned and compared
in search for predictive biomarker signatures (B right). The accessibility of murine central nervous systems provides the possibility to search for the underlying
mechanisms that shape antidepressant treatment response, ultimately leading to novel drug targets and mechanisms (B left).
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more complex behavioral signatures of antidepressant treatment
response. Future studies should implement cluster analyses of
phenotypic outcomes, e.g., by automated behavioral analysis in
the home cage of an animal.
To develop an approach for identifying stratification into
different subpopulations out of a large number of responding
animals using a low-cost animal model, we recently established
an animal experimental paradigm where we analyzed the
behavioral responses of a group of zebrafish subjected to stress
exposure. As a vertebrate, zebrafish show high homology of the
major neuromodulatory circuits involved in stress and emotional
regulation. Further they exhibit behavioral phenotypes for
identifying “depression-like” indices and are sensitive to different
psychotropic drugs (28, 29). However, so far the studies focused
on average population effect of drug treatments on behavior and
have not carefully considered the heterogeneity and individuality.
Our results suggest the existence of a clear stratification in
the behavioral outcomes following stress exposure in zebrafish
(Beckmann, Cook, and Ryu, unpublished data). Given the fact
that zebrafish are cheap to maintain in large numbers and genetic
manipulations of their genome are quite easy, they provide a
powerful complimentary animal model to rodents for testing
heterogeneity of antidepressant responses.
Thus, we propose to consider individual outcomes and
meaningful stratification of the experimental group instead
of average group effects in animal models of depression and
response prediction to improve translation between preclinical
research and clinical trials. As shown in recent examples,
this strategy could contribute to increased success rate when
extrapolating results from the bench to the bedside and back
(26, 30).
A PLEA FOR CAREFUL TRANSLATIONAL
AND TRANSDIAGNOSTIC RESEARCH IN
PSYCHIATRY
It is still a long way to go for personalized medicine and
clinically embedded prediction assays for mental illnesses.
Current developments neither predict nor monitor disease
state nor help with the antidepressant drug choice (31).
Huge efforts have been undertaken in the fields of functional
neuroimaging, electrophysiology, genetics and gene expression
(31), immune mechanisms, neuroendocrine challenge tests such
as the combined dexamethasone CRH challenge test, and
polysomnography (32). However, we have to admit that despite
decades of research, scientists have been unable to find any
genetic or neurological evidence to support the breakdown
of psychiatric disorders into the diagnostic categories such as
provided in the DSM or ICD (33). So far, no cellular or genetic
signatures for any mental disorder have been discovered, nor
has anyone developed reliable biomarkers, blood tests, or brain
scans that match perfectly with a DSM-defined mental illness.
Because the focus of the field has been solely on understanding
mental disorders as defined by the clusters of symptoms in the
DSM, most current treatments have aimed at relieving symptoms
rather than resolving the underlying pathology. For example,
psychiatrists can reduce hallucinations, but they are not treating
schizophrenia. They can relieve symptoms of depression, but
that may not be treating the underlying disorder. To overcome
these substantial and diagnosis-inherent problems, an ongoing
initiative, the Research Domain Criteria (RDoC) initiative from
the National Institute of Mental Health (NIMH), proposes
behavioral domains, which are shared across several species
and in many contexts. Using the RDoC approach, scientists are
trying to better understand mental illnesses by focusing on the
convergence of biology and behavior and tying different aspects
of behavioral, cognitive, and emotional functions to specific brain
systems. The research is organized into broad domains, namely
positive valence (seeking and appreciating reward), negative
valence (threat and loss), cognitive systems, social processes, and
arousal and regulatory systems (34).
Focusing on domain-based inclusion criteria for human
studies bridges the gap toward animal research by overcoming
the artificial, highly heterogeneous, category-based DSM-5
or ICD-10 diagnostic criteria. For a recent excellent review
about the integration of RDoC criteria in animal models of
psychiatric disorders see (35). Traditionally, animal experimental
approaches have always been focusing on core symptoms of
mental disorders. Whereas some time ago, the limitation to
specific core symptoms has been considered a major drawback of
animal models, nowadays and in the context of RDoC, this could
now turn out to be an advantage.
Initiatives like RDoC might also solve or at least reduce
the reproducibility problem. In a 2006 report, Hackam and
colleagues showed that from 76 top-quality animal studies, only
37% could be replicated in humans, 18% were contradicted, and
34% still remained untested in humans (36). The median time of
translation from animal to human was 7 years (36). Experiments
and studies are usually designed and performed separately for
animals and humans, leading to different parameters, different
research questions, the involvement of different experimenters,
thus increasing confounding variables. These problems might be
overcome by a careful and prospectively planned combination
of animal and human experiments within the same project, just
as proposed by Kurian and colleagues (37) in 2011. Such an
approach could shift the focus toward truly translational research
projects, bridging the gap between animals and humans. Recent
publications with significant impact on the field have shown
that this strategy could indeed serve as a template for successful
approaches into complex psychiatric diseases: combining data
from animal stress models with human data, the Nestler group
could reveal sex-specific transcriptome differences in depression
(38). Focusing on response to antidepressant treatment, we could
identify response-associated transcript profiles in peripheral
blood samples of mice, predicting antidepressant treatment
response with an accuracy of almost 80% in a patient population
(26). Those and other (39, 40) examples of translational studies
are encouraging. Importantly, for any translational approach
in psychiatry, the research questions originating from the
daily clinical situation (i.e., Why does one patient respond to
the antidepressant, whereas another does not? What are the
neurobiological mechanisms underlying clinical improvement?)
need to be first defined and then carefully translated into an
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animal experimental approach. To tackle this challenge, a close
interaction between clinician scientists from neuropsychiatry
and basic researchers, which are dedicated to address clinically
relevant questions, is mandatory.
In conclusion, we hope to have convinced the reader that
animal models are pivotal in the effort to translate basic
progress into better care. Because of practical and ethical
limitations to dissecting neurobiological disease mechanisms
in humans, continued progress will critically depend on our
ability to emulate aspects of depressive symptomatology and
treatment response in nonhuman organisms. Still, a significant
challenge remains how to effectively align variables measured
in animals with those assessed in human studies, i.e., in
genetic studies or during the various phases of development of
novel antidepressant compounds. This can only be achieved if
translation is prospectively planned, allowing for the best possible
match of recorded data across species. Translational psychiatry
is a two-way bridge: research questions ideally emerge as a well-
defined, clinically relevant problem that needs to be carefully
translated into the best-possible animal experimental approach.
On the other hand, preclinical research needs to inform clinical
trials and diagnosis. Recent successful examples in depression
research are encouraging and might serve as a template for
future approaches into the neurobiology of this devastating and
pervasive disorder.
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